The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase — from $34 a month to $51 — by switching to lower-cost plans during the program’s open enrollment period, which runs through Dec.
You don't have permission to access "http://www.medpagetoday.com/washington-watch/washington-watch/123652" on this server. Reference #18.d494d817.1793332899.22e6a54f https://errors.edgesuite.net/18.d494d817.1793332899.22e6a54f
3 min read IF ANYONE CAN MAKE RATTAN hot, it’s Alexander Skarsgård. The actor’s latest film project, about a craftsman who creates a wicker husband (Skarsgård) for a lonely woman (played by Olivia Colman), has been an unlikely hit since its release in theaters last week. But basket weave isn’t the only material Skarsgård’s rocking—he’s
PAGE, Ariz. — Doug Herrera still lives in the house his father built, though his dad died some time ago from cancer. Herrera wonders if that illness could have been linked to pollutants from nearby uranium mining. Now, he worries that a possible new neighbor — a proposed $10 billion mega data center — could
No New Cases Today, Says Joint Information Center; However, Three Cases This Month Have Been Acquired Though Community Transmissoin
Press release from the Humboldt County Joint Information Center:
Humboldt County’s COVID-19 case count stands at 105 as no new cases were confirmed today. Two previous cases that had been under investigation were determined to be acquired through community transmission.
Humboldt County has seen three new cases attributed to community transmission this month alone. “These are individuals without a history of travel or exposure to a known case,” Humboldt County Health Officer Dr. Teresa Frankovich said. “This just points to the fact that virus is circulating in our community and will increase as we ease out of shelter in place and become more interactive again. Prevention measures will become increasingly important.”
Follow us on Facebook: @HumCoCOVID19, Instagram: @HumCoCOVID19, Twitter: @HumCoCOVID19, and Humboldt Health Alert: humboldtgov.org/HumboldtHealthAlert
###
Yesterday
=historic data. All data from the Humboldt County Joint Information Center.
Cases
Case Updates
2 new recovered cases.
2 cases under investigation were determined as being acquired through community transmission.
The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase — from $34 a month to $51 — by switching to lower-cost plans during the program’s open enrollment period, which runs through Dec.
You don't have permission to access "http://www.medpagetoday.com/washington-watch/washington-watch/123652" on this server. Reference #18.d494d817.1793332899.22e6a54f https://errors.edgesuite.net/18.d494d817.1793332899.22e6a54f
The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase — from $34 a month to $51 — by switching to lower-cost plans during the program’s open enrollment period, which runs through Dec.
You don't have permission to access "http://www.medpagetoday.com/washington-watch/washington-watch/123652" on this server. Reference #18.d494d817.1793332899.22e6a54f https://errors.edgesuite.net/18.d494d817.1793332899.22e6a54f